DK2421534T3 - Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin - Google Patents

Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin

Info

Publication number
DK2421534T3
DK2421534T3 DK10714164.0T DK10714164T DK2421534T3 DK 2421534 T3 DK2421534 T3 DK 2421534T3 DK 10714164 T DK10714164 T DK 10714164T DK 2421534 T3 DK2421534 T3 DK 2421534T3
Authority
DK
Denmark
Prior art keywords
dimethylphenylsulphanyl
piperazine
phenyl
salts
liquid formulations
Prior art date
Application number
DK10714164.0T
Other languages
English (en)
Inventor
Svend Treppendahl
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2421534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK2421534T3 publication Critical patent/DK2421534T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08Lactic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
DK10714164.0T 2009-04-24 2010-04-16 Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin DK2421534T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21454009P 2009-04-24 2009-04-24
DKPA200900531 2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en) 2009-04-24 2010-04-16 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
DK2421534T3 true DK2421534T3 (da) 2014-10-13

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10714164.0T DK2421534T3 (da) 2009-04-24 2010-04-16 Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin

Country Status (35)

Country Link
US (4) US8940746B2 (da)
EP (1) EP2421534B1 (da)
JP (1) JP5722879B2 (da)
KR (1) KR101779214B1 (da)
CN (2) CN102405048A (da)
AR (2) AR076400A1 (da)
AU (1) AU2010238946B2 (da)
BR (1) BRPI1015338C1 (da)
CA (1) CA2759456C (da)
CL (1) CL2011002631A1 (da)
CO (1) CO6450649A2 (da)
CR (1) CR20110554A (da)
DK (1) DK2421534T3 (da)
DO (2) DOP2011000319A (da)
EA (1) EA021122B1 (da)
ES (1) ES2512719T3 (da)
GE (1) GEP20135938B (da)
HK (1) HK1206732A1 (da)
HR (1) HRP20140880T1 (da)
IL (1) IL215362A0 (da)
MA (1) MA33298B1 (da)
MX (1) MX2011011119A (da)
MY (1) MY155288A (da)
NZ (1) NZ596431A (da)
PL (1) PL2421534T3 (da)
PT (1) PT2421534E (da)
RS (1) RS53539B1 (da)
SG (1) SG175124A1 (da)
SI (1) SI2421534T1 (da)
SM (1) SMT201400159B (da)
TN (1) TN2011000504A1 (da)
TW (1) TWI461224B (da)
UA (1) UA106985C2 (da)
WO (1) WO2010121621A1 (da)
ZA (1) ZA201107731B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット 1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジンの塩の液体製剤
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
CA2916175A1 (en) * 2013-07-01 2015-01-08 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2017137048A1 (en) 2016-02-08 2017-08-17 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
RU2018144248A (ru) 2016-07-01 2020-08-03 Х. Лундбекк А/С Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药(厦门)有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE602004016316D1 (de) 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
CN101472906B (zh) * 2006-06-16 2012-04-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
EP2044020B1 (en) * 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット 1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジンの塩の液体製剤

Also Published As

Publication number Publication date
JP2012524735A (ja) 2012-10-18
BRPI1015338A2 (pt) 2016-05-31
NZ596431A (en) 2012-12-21
US20190167667A1 (en) 2019-06-06
EA021122B1 (ru) 2015-04-30
BRPI1015338C1 (pt) 2021-08-10
AU2010238946B2 (en) 2013-03-28
US20170224677A1 (en) 2017-08-10
AU2010238946A1 (en) 2011-12-08
PT2421534E (pt) 2014-10-29
IL215362A0 (en) 2011-12-29
HK1206732A1 (en) 2016-01-15
CA2759456A1 (en) 2010-10-28
US20120035188A1 (en) 2012-02-09
EA201171287A1 (ru) 2012-04-30
SG175124A1 (en) 2011-12-29
MY155288A (en) 2015-09-30
DOP2011000319A (es) 2012-02-29
SMT201400159B (it) 2015-01-15
GEP20135938B (en) 2013-10-10
KR20120022809A (ko) 2012-03-12
ES2512719T3 (es) 2014-10-24
KR101779214B1 (ko) 2017-09-18
MX2011011119A (es) 2011-11-04
RS53539B1 (en) 2015-02-27
AR122051A2 (es) 2022-08-10
CN104693145A (zh) 2015-06-10
CL2011002631A1 (es) 2012-04-09
JP5722879B2 (ja) 2015-05-27
US8940746B2 (en) 2015-01-27
US10857149B2 (en) 2020-12-08
ZA201107731B (en) 2013-02-27
CN102405048A (zh) 2012-04-04
BRPI1015338B8 (pt) 2021-05-25
US20150094316A1 (en) 2015-04-02
HRP20140880T1 (hr) 2014-11-07
DOP2012000211A (es) 2013-03-31
TW201041604A (en) 2010-12-01
BRPI1015338B1 (pt) 2021-01-05
SI2421534T1 (sl) 2014-11-28
EP2421534A1 (en) 2012-02-29
US9475748B2 (en) 2016-10-25
TN2011000504A1 (en) 2013-05-24
MA33298B1 (fr) 2012-05-02
UA106985C2 (uk) 2014-11-10
WO2010121621A1 (en) 2010-10-28
US10034876B2 (en) 2018-07-31
CA2759456C (en) 2017-10-31
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
AR076400A1 (es) 2011-06-08
CO6450649A2 (es) 2012-05-31
PL2421534T3 (pl) 2014-12-31
TWI461224B (zh) 2014-11-21

Similar Documents

Publication Publication Date Title
DK2421534T3 (da) Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
DK2470166T3 (da) Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
CL2014001765A1 (es) Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
CO6811863A2 (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
DK2054394T3 (da) Piperazinforbindelser med herbicid virkning
BR112013033511A2 (pt) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6 - pentahidroxihexil)ethóxi)fenil)butil)carbamimidoil) pirazina-2-carboxamida
IL216280A0 (en) Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4-(dimethylamino)butyl 2-(4-(2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate
DK3252069T3 (da) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
DK2753306T3 (da) Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
ITMI20110647A1 (it) Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
DK2129377T3 (da) Flydende formuleringer af salte af 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin
CY1115793T1 (el) Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)